arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Organogenesis Holdings Inc.

ORGO
$1.45 ▼ -0.02 (-1.02%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
43 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
50
Health
Fair
Neutral
auto_awesome

Analytical Summary

Organogenesis Holdings Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $186.6M
Dividend Yield —
Revenue Growth -56.7% →
Op. Margin -116.5% ↗
ROIC -65.1% ↘
FCF / Share $-0.25 ↘
Trailing P/E —
Price / Book 1.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

43-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$43.76M
↓ -56.7% —
Net Income Profit after all expenses
$-96.27M
↓ -925.0% —
Operating Margin Operating profit as % of sales
-116.5%
↑ +37.0% 51th
FCF / Share Free cash flow per share
$-0.25
↓ -280.9% —
Long-Term Debt Long-term obligations
$62.34M
↓ -2.2% —

Health Breakdown

Profitability ↓
41
Returns ↓
75
Cash Quality
12

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 43 quarters